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tissue. In humans, chronic and acute 
ureteral obstruction can occur in vari-
ous clinical situations, such as ureteral 
stone or ureteral carcinoma. Most pub-
lished work examined PPAR-  levels in 
cell-line models, but none correlated 
PPAR-  levels in kidney tissue from 
patients with chronic obstructive neph-
ropathy at various stages of develop-
ment. Second, it is interesting that Boor 
 et al. 3 discovered no signifi cant diff er-
ences in renal fi brosis between PPAR-  -
deficient (PPAR-   – / –  ) and wild-type 
animals. Although the authors offer 
some reasonable explanations, these 
remain unsatisfying to explain the ben-
efi t of BAY PP1 therapy in chronic kid-
ney disease, of which renal fi brosis is a 
major manifestation. It also raises the 
possibility that BAY PP1 may act partly 
through PPAR-independent pathways, 
depending on the model used, as has 
similarly been seen with other PPAR-  
agonists. 9 Park  et al. 10 induced diabetes 
in PPAR-  knockout mice and found 
increased profi brotic and proinfl amma-
tory eff ects; thus, more experiments with 
BAY PP1 might be needed in PPAR-  
knockout animals, but with modi-
fications to experimental conditions. 
Th ird, it would be interesting to conduct 
a time-course analysis in UUO models 
to determine possibly early progressive 
onset of PPAR-  expression. 
 In conclusion, the findings of Boor 
 et al. 3 (summarized in  Table 1 ) represent 
exciting work on a novel PPAR-  agonist, 
BAP PP1, that is potentially capable of 
ameliorating renal fi brosis and improving 
renal function. It would be unfair to com-
pare the perfor mance of BAY PP1 to that 
of other currently available PPAR-  ago-
nists, as more research is needed for this 
assessment. Indeed, future studies should 
examine BAY PP1 ’ s safety and effi  cacy, 
as well as its molecular and cellular inter-
actions. So, this Jedi needs to be curbed 
before it is ready to intervene against 
renal fi brosis. 
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 Old friends form alliance 
against podocytes 
 Matias  Simons 1 , 2 , 3 and  Tobias B.  Huber 2 , 4 
 Wang and colleagues identify the activation of Wnt signaling as an 
important downstream event in transforming growth factor-  -
mediated podocyte injury. Supported by other recent studies, canonical 
Wnt signaling is emerging as a critical stress pathway in podocytes and 
may be exploited for therapeutic strategies in the treatment of 
glomerulopathies. 
 Kidney International (2011)  80, 1117 – 1119.  doi: 10.1038/ki.2011.298 
 Animal development and homeostasis 
require a set of highly conserved cell-sig-
naling pathways (including Wnt, trans-
forming growth factor-  , Hedgehog, 
receptor tyrosine kinase (RTK), Notch, 
JAK / STAT, and mTOR) that are used 
repeatedly in diff erent spatial and tempo-
ral contexts. In recent years, research has 
also focused on the cross-talk among 
these major signaling pathways. Th e cross-
talk between the transforming growth 
factor-  (TGF-  ) / bone morphogenetic 
protein (BMP) and Wnt pathways is prob-
ably the most extensively studied. Th e two 
pathways show strong interactions 
throughout the life of an animal, also on 
the molecular level. TGF-  / BMP and Wnt 
proteins are secreted ligands that form 
overlapping extracellular gradients during 
embryonic development. In the  Drosophila 
wing disc, for example, the concerted 
action of orthogonal gradients of Wg and 
a member of the TGF-  family of secreted 
factors, Decapentaplegic (Dpp), deter-
mines the shape of the wing. Also in the 
responding cells, a number of  cytoplasmic 
interactions between components of these 
pathways fi ne-tune their respective signal-
ing. Th e hot spot of TGF-  / Wnt cross-
talk, however, is the nucleus.   -catenin 
and Lef1 / Tcf, which are downstream 
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components of the Wnt signaling cascade, 
can form a complex with the TGF-  sign-
aling transducer Smad to synergistically 
regulate gene expression. Th is is best illus-
trated in the Spemann ’ s organizer of  Xeno-
pus laevis , another famous example in 
develop mental biology. 1 In some contexts, 
the two pathways can also show antago-
nistic behavior. While the Wnt pathway 
oft en orchestrates mesenchymal – epithe-
lial transition, such as in the developing 
kidney during metanephric mesoderm 
induction, TGF-  signaling is known to 
promote the conversion of epithelia to 
mesenchyme in fi brotic events. 
 Wang  et al. 2 (this issue) report on how 
TGF-  signaling and Wnt signaling inter-
act in podocytes. Interestingly, both path-
ways have independently been identifi ed 
as key factors in the progression of 
glomerular failure. Increased TGF-  
activity in podocytes, typically, leads to 
apoptosis and / or detachment of podo-
cytes from the glomerular basement 
membrane, initiating the development of 
glomerulosclerosis. Podocyte cell death 
seems to be mediated by a number of 
different TGF-  -dependent pathways, 
including nuclear factor-  B inhibition 3 
and Notch activation. 4 The article by 
Wang  et al. 2 now adds another important 
downstream event to the TGF-  signaling 
node in the podocyte. Th e authors dem-
onstrate that several Wnts, in particular 
Wnt1, are upregulated in response to 
ectopic expression of TGF-  1, which sub-
sequently leads to   -catenin activation. 
Importantly, the Wnt antagonist Dkk1 is 
eff ective in blocking TGF-  1-mediated 
  -catenin activation  in vivo , resulting 
in diminished podocyte injury and 
albuminuria. Th ese fi ndings are highly 
relevant to human glomerular disease, as 
upregulated Wnt expression has been 
associated with diabetic nephropathy and 
focal segmental glomerulosclerosis. 5,6 
Consistent with these fi ndings, several 
recent studies demonstrated that the 
genetic or pharmacological inhibition of 
Wnt /  -catenin signaling ameliorates 
glomerular disease. 5 – 7 
 Most of the major signaling pathways 
are vital during the early stages of glomer-
ular development, when nascent cells 
acquire their identities to organize kidney 
architecture. However, the same pathways 
seem to interfere with the later function 
of mature podocytes. Recent examples of 
such a failed  ‘ compensatory attempt ’ of 
developmental programs during glomer-
ular injury are deregulated mTOR, 8,9 
Notch, 4 and Wnt signaling in podocytes. 
Th erefore, it could indeed be a key feature 
of podocyte injury that developmental 
programs are being reactivated in glomer-
ular diseases. The effect on podocyte 
behavior is still rather unclear in this con-
text. Wang  et al. 2 demonstrate that 
enhanced Wnt signaling in adult podo-
cytes leads to the upregulation of mesen-
chymal markers as well as a  ownregulation 
of nephrin expression. In another recent 
study, it was shown that loss of Wnt sign-
aling enhanced podocyte adhesiveness 
and diff erentiation. 6 Th erefore, canonical 
Wnt signaling seems to promote a dedif-
ferentiated and more mesenchymal podo-
cyte phenotype, resulting in the inability 
of the adult podocyte to maintain the 
complex three-dimensional architecture 
of the fi ltration barrier. In the kidney, the 
tuning down of Wnt signaling during 
development and diff erentiation is critical 
not only in the glomerulus but also for 
terminal differentiation of tubular 
epithelial cells and the prevention of 
 overproliferation of kidney tubules and 
polycystic kidney disease. 10 
 But why is the glomerulus reviving 
potentially harmful developmental pro-
grams in response to injury? A possible 
explanation may be that these programs 
control the proliferation of glomerular 
progenitor cells. In this respect, it has been 
shown that Notch activation stimulates 
renal progenitors, while a downregulation 
of the Notch pathway is required for their 
specifi cation toward the podocyte line-
age. 11 Renal progenitors of the glomerulus 
can be found within the parietal epithe-
lium of the Bowman ’ s capsule. Consistent 
with this, the immunohistochemical 
analysis by Wang  et al. 2 seems to show 
upregulated Wnt1 expression not only in 
the podocyte (in response to TGF-  ), but 
also in the parietal cells. 2 Apart from 
Notch, Wnt is also a prominent player in 
stem-cell control and vertebrate regenera-
tion. Th us, a glomerulus-wide increase in 
Wnt1 aft er injury might promote repair 
processes via the progenitor cells but at 
the same time harm the adult podocytes 
by causing their detachment and dedif-
ferentiation ( Figure 1 ). 
 In summary, the study by Wang  et al. 2 
emphasizes once again the importance of 
the Wnt pathway in the podocyte as well 
as the inhibition of Wnt signaling as a 
potential therapeutic strategy in glomer-
ular disease. Th e study also introduces a 
novel pathway for Wnt activation. Th is 
time, activation is via an old friend —
 TGF-  . 
 DISCLOSURE 













 Figure 1 | TGF-b1-mediated activation of Wnt signaling leads to podocyte stress and injury. 
One hypothetical reason for reactivation of this developmental pathway could be the stimulation 
of progenitor cells for glomerular regeneration. A similar balance between podocyte death and 
repair has recently been shown for the Notch pathway.
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 Blockade of PDGF 
receptor signaling reduces 
myofibroblast number and 
attenuates renal fibrosis 
 Valerie S.   LeBleu 1 and  Raghu  Kalluri 1 , 2 , 3  
 Fibrosis can be considered as wound healing that never ceases, and 
activated fibroblasts (myofibroblasts) probably play a critical role 
in this unabated tissue repair process. In the setting of renal fibrosis, 
two central questions remain unanswered: Where do activated 
myofibroblasts come from; and what mechanism or mechanisms 
keep them activated? The study by Chen and colleagues addresses 
the role of platelet-derived growth factor receptor (PDGFR) signaling in 
the activation of myofibroblasts. 
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 Fibrosis can be considered as wound 
healing that never ceases. In the setting of 
tissue repair, myofi broblasts appear in 
conjunction with infl ammatory response 
to provide the required physical and bio-
chemical support to enable regeneration, 
upon which all repair activities come to a 
halt with the disappearance of activated 
myofi broblasts and infl ammation. In the 
kidney, acute injury is associated with 
such plastic response, whereas in the 
chronic injury setting, the resolution 
phase associated with such regenerative 
process is impaired, resulting in unabated 
repair that leads to what is referred to as 
fi brosis. Although many key questions 
remain unanswered with regard to the 
mechanism behind organ fi brosis, the 
kidney is offering an excellent model 
system to systematically probe them. Two 
central questions that remain are: Where 
do activated fi broblasts (myofi broblasts) 
come from; and what mechanism or 
mechanisms keep them activated? In 
the study by Chen and colleagues 1 (this 
issue), the role of platelet-derived growth 
factor receptor (PDGFR) signaling in 
the activation of myofibroblasts is 
addressed. 
 Chen and colleagues 1 demonstrate that 
altered PDGF – PDGFR signaling is associ-
ated with kidney fibrosis, and provide 
compelling evidence for the role of 
PDGFR signaling in myofi broblast activa-
tion. Although the total number of 
PDGFR  /    +   cells (presumably interstitial 
cells) was not quantifi ed in this study, the 
authors clearly demonstrate an increase in 
expression of specifi c components of the 
PDGF – PDGFR signaling axis in renal 
fi brosis, with a robust increase in PDGF-A 
through PDGF-D and PDGFR  and 
PDGFR  . Th e use of anti-PDGFR  (1E10) 
and anti-PDGFR  (2C5) antibodies from 
ImClone Systems reduces the observed 
increase in PDGF and PDGFR gene 
expression in mouse fi brotic kidney and 
subsequently reduces the activation of 
PDGFR  and PDGFR  . By this approach, 
a marked decrease in the number of 
  -smooth muscle actin-positive (  SMA   +   ) 
interstitial myofibroblasts and overall 
COL1A1 and COL3A1 gene expression is 
noted. Th e authors suggest that impaired 
macrophage recruitment due to dimin-
ished PDGFR  /  signaling with the use 
of anti-PDGFR  /  antibodies, as well as 
imatinib mesylate (which also targets 
PDGFR  signaling), improves renal fi bro-
sis. Th is study by Chen and colleagues 1 is 
supported by published fi ndings of Wang 
and colleagues 2 which showed that imat-
inib mesylate might reduce renal fi brosis 
in unilateral ureteric obstruction in mice, 
and also by the studies by Lassila and col-
leagues 3 using mice with diabetic neph-
ropathy. Together these studies raise the 
interesting possibility that targeting 
PDGFR signaling might off er new thera-
peutic avenues for renal fi brosis, perhaps 
by reducing macrophage infi ltration. 
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